A Comprehensive Investigation of the Potential Role of Lipoproteins and Metabolite Profile as Biomarkers of Alzheimer’s Disease Compared to the Known CSF Biomarkers

Table 1

Demographics and clinical characteristics of patients.

Measure	Apo-E status		value
	Negative	Positive
	Age (years)				0.019
Gender
Male	42	86	0.066
Female	29	64
Education (years)			0.183
CDR			0.501
ADAS			0.381
CSF proteins
Aβ-42			<0.001
TAU			0.215
P-TAU			0.067
Lipoproteins and metabolite
Phenylalanine			0.049

Only lipoproteins and metabolites with significant or marginally significant differences mentioned in the table. CDR: clinical dementia rating, ADAS: Alzheimer’s disease assessment scale, CSF: cerebrospinal fluid.